RSS   Newsletter   Contact   Advertise with us
Post Online Media

ESSA Pharma appoints Peter Virsik as EVP and COO

ESSA PharmaESSA Pharma Inc., a clinical-stage pharmaceutical company, announces the appointment of Peter Virsik as executive vice president & chief operating officer.
Article continues below

READ MORE ESSA Bancorp appoints William A. Viechnicki as chairman

Prior to joining ESSA, Mr. Virsik served as Senior Vice President, Corporate Development for XenoPort (acquired by Arbor Pharmaceuticals), leading licensing, strategy, new product planning and alliance management for the company.

During his tenure at XenoPort, Mr. Virsik played an integral role in the licensing and commercialization of Horizant (gabapentin enacarbil).

Prior to XenoPort, Mr. Virsik worked for Gilead Sciences from 2000 through 2005 in Corporate Development, where he was involved in building Gilead’s HIV franchise through the acquisition of Triangle Pharmaceuticals and the licensing of Vitekta (elvitegravir).

Before joining Gilead, he worked at J.P. Morgan in the biotechnology equity research group and as a consultant for Ernst and Young.

Mr. Virsik began his career in R&D at Genentech.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy